Effective therapies are still urgently needed for patients with brain metastases from cutaneous melanoma. Using preclinical mouse models, researchers are investigating the role of focal adhesion kinase (FAK) in distant cutaneous melanoma metastases and the pharmacologic inhibition of FAK, both alone and in combination with rapidly accelerated fibrosarcoma/mitogen-activated protein kinase (RAF/MEK) pathway inhibition.
2025
China’s NMPA Approves Toripalimab in First-Line Melanoma
China’s NMPA has approved the sNDA for toripalimab as a first-line treatment for patients with unresectable or metastatic melanoma.
Moffitt Study Uncovers a Way To Boost Treatment for Aggressive Melanoma
A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable. Results of the study were presented at the American Association for Cancer Research annual meeting and published in Cancer Reseach.
“One of the Harder Decisions”: Adjuvant Therapy for Stage II Melanoma
Two anti-PD-1 agents are currently approved for adjuvant therapy for patients with stage II melanoma. Experts say that treatment decisions for these patients are not always clear cut and that individual factors weigh in heavily. Listen as Allison Betof Warner, MD, PhD, from Stanford University, Rodabe N. Amaria, MD, from the University of Texas MD Anderson Cancer Center, and Sapna Patel, MD, from the University of Colorado, discuss the results of the CheckMate 238 trial and how those findings inform their care decisions, as well as how they approach complex discussions with these patients.